These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6438979)

  • 21. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis.
    Feutren G; Friend D; Timonen P; Barnes A; Laburte C
    Br J Dermatol; 1990 Jun; 122 Suppl 36():85-93. PubMed ID: 2369572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation.
    Thiel G; Harder F; Lörtscher R; Brünisholz M; Landmann J; Brunner F; Follath F; Wenk M; Mihatsch M
    Klin Wochenschr; 1983 Oct; 61(20):991-1000. PubMed ID: 6358654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine metabolite pattern in blood from patients with acute GVHD after BMT.
    Christians U; Spiekermann K; Bader A; Schottmann R; Linck A; Wonigeit K; Sewing KF; Link H
    Bone Marrow Transplant; 1993 Jul; 12(1):27-33. PubMed ID: 8374534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation.
    Ratanatharathorn V; Uberti J; Karanes C; Lum LG; Abella E; Dan ME; Hussein M; Sensenbrenner LL
    Bone Marrow Transplant; 1994 May; 13(5):625-30. PubMed ID: 8054915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
    Weaver CH; Clift RA; Deeg HJ; Storb R; Appelbaum FR; Bensinger W; Doney K; Hansen JA; Martin PO; Sanders J
    Bone Marrow Transplant; 1994 Dec; 14(6):885-93. PubMed ID: 7711667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporin A induces a selective, reversible suppression of T-helper lymphocyte regeneration after syngeneic bone marrow transplantation: association with syngeneic graft-versus-host disease in rats.
    Bos GM; Majoor GD; van Breda Vriesman PJ
    Clin Exp Immunol; 1988 Dec; 74(3):443-8. PubMed ID: 2976623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A.
    Hunter AE; Bessell EM; Russell NH
    Bone Marrow Transplant; 1992 Nov; 10(5):431-4. PubMed ID: 1464005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood cyclosporin concentrations but not doses correlate with acute changes in renal function following heart and heart-lung transplantation.
    Trull AK; Best NG; Tan KK; Hue KL; Higenbottam TW; Large S; Wallwork J
    Ther Drug Monit; 1992 Aug; 14(4):275-80. PubMed ID: 1519300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow transplantation: effects of conditioning and cyclosporin prophylaxis on microvascular permeability to a small solute (technetium 99m diethylene triamine penta-acetic acid).
    Peters AM; Vassilarou DS; Hows JM; Ballardie FW
    Eur J Nucl Med; 1991; 18(3):199-202. PubMed ID: 2040341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients.
    Lindholm A; Ringdén O; Lönnqvist B
    Transplantation; 1987 May; 43(5):680-4. PubMed ID: 3554661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bone marrow transplantation in leukemia and aplastic anemia].
    Speck B; Gratwohl A; Nissen C; Osterwalder B; Signer E; Jeannet M
    Schweiz Med Wochenschr; 1983 Apr; 113(17):622-9. PubMed ID: 6346483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
    Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD
    J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T; Akatsuka Y; Towatari M; Takeyama K; Miyamura K; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporin-associated nephropathy in patients with autoimmune diseases.
    Mihatsch MJ; Bach JF; Coovadia HM; Førre O; Moutsopoulos HM; Drosos AA; Siamopoulos KC; Noël LH; Ramsaroop R; Hällgren R
    Klin Wochenschr; 1988 Jan; 66(2):43-7. PubMed ID: 3347004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.
    Ringdén O; Bäckman L; Lönnqvist B; Heimdahl A; Lindholm A; Bolme P; Gahrton G
    Bone Marrow Transplant; 1986 May; 1(1):41-51. PubMed ID: 3332119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.
    Deeg HJ; Spitzer TR; Cottler-Fox M; Cahill R; Pickle LW
    Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.